(Q44197094)

30 November 2017

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma (English)

1 reference

30 November 2017

4

1 reference

30 November 2017

7

1 reference

30 November 2017

6

Judith Manola

1 reference

30 November 2017

Matthew R Smith

1

1 reference

30 November 2017

Donald Kaufman

series ordinal

2

1 reference

30 November 2017

Daniel George

series ordinal

3

1 reference

30 November 2017

Maryanne Kazanis

series ordinal

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

95

1 reference

30 November 2017

9

1 reference

30 November 2017

1864-1868

1 reference

Estrogen receptor beta in prostate cancer: brake pedal or accelerator?

30 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Phase II trial of tamoxifen in metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Tamoxifen in advanced prostate cancer: An ECOG pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Tamoxifen in advanced prostatic carcinoma. A dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10844

21 January 2018

Identifiers

DOI

10.1002/CNCR.10844

1 reference

30 November 2017

1 reference